GlassScriptPhysician profile
David Gabbaizadeh
NPI 1194722009
$7,026.01
in general payments reported to CMS, 2019-2025
39 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $405 · 2021: $930 · 2022: $922 · 2023: $1,542 · 2024: $1,315 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996 · Education: $95.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,995.85 |
| Education | $95.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,937.71 | 2019-2025 | |
| Janssen Biotech, INC. | $695.19 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $463.53 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $441.12 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $344.37 | 2019-2023 | Entyvio, Gattex, Gammagard Liquid |
| Lilly USA, LLC | $296.59 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $222.37 | 2019-2024 | Suflave, Sutab |
| Redhill Biopharma INC. | $208.12 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $198.67 | 2022-2025 | Ocaliva |
| Daiichi Sankyo INC. | $185.47 | 2019-2024 | Injectafer |
| Ferring Pharmaceuticals INC. | $163.71 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $151.16 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $148.27 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $143.00 | 2022-2023 | Dupixent |
| Horizon Therapeutics Plc | $124.99 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gabbaizadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.